Aligos Therapeutics (ALGS) Non-Current Assets (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Non-Current Assets for 8 consecutive years, with $4.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets fell 37.89% year-over-year to $4.2 million; the trailing twelve-month figure through Jun 2026 stood at $21.1 million (down 31.43% YoY), and the FY2025 full-year result was $5.7 million, down 28.69% from the prior year.
• Non-Current Assets fell to $4.2 million in Q2 2026 per ALGS's latest filing, from $4.9 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $15.4 million in Q1 2022 and bottomed at $4.2 million in Q2 2026.
• Historically, Non-Current Assets has averaged $9.7 million across 5 years, with a median of $9.5 million in 2024.
• The widest YoY moves for Non-Current Assets: up 4.62% in 2022, down 57.51% in 2022.
• Over 5 years, Non-Current Assets stood at $13.1 million in 2022, then decreased by 20.57% to $10.4 million in 2023, then slipped by 23.84% to $8.0 million in 2024, then retreated by 28.69% to $5.7 million in 2025, then decreased by 25.94% to $4.2 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $4.2 million, $4.9 million, and $5.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.